A
BCRX icon

AlphaQuest’s BioCryst Pharmaceuticals BCRX Stock Holding History

AlphaQuest’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-76,405
Closed -$596K – 239
2025
Q4 		$596K Buy
76,405
+12,302
+19% +$88.9K 0.03% 695
2025
Q3 		$487K Sell
64,103
-21,250
-25% -$177K 0.03% 809
2025
Q2 		$765K Buy
85,353
+22,707
+36% +$211K 0.08% 410
2025
Q1 		$470K Buy
62,646
+34,204
+120% +$276K 0.05% 552
2024
Q4 		$214K Buy
28,442
+25,282
+800% +$192K 0.03% 845
2024
Q3 		$24K Buy
+3,160
New +$24K ﹤0.01% 1495

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

AlphaQuest's BCRX Position: Q1 2026 in Review

AlphaQuest sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 76,405 shares — an estimated $596K sold.

AlphaQuest first reported a position in BCRX in Q3 2024 and held it in 6 quarters. The position peaked at $765K in Q2 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • AlphaQuest reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 76,405 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $596K.
  • AlphaQuest first reported a position in BioCryst Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • AlphaQuest's BioCryst Pharmaceuticals position peaked at $765K in Q2 2025.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.